Premier Alternatives

Noveome Biotherapeutics

Pittsburgh, PA · Founded 2000 · Privately Held (backing)

Developer of novel biotherapeutic products designed to treat inflamed or damaged tissues. Noveome Biotherapeutics is based in Pittsburgh, PA and was founded in 2000. Its last reported valuation was $200 million in Apr 2019. It has raised $78.7 million across 4 recorded rounds; the latest was a $36.2 million early-stage round in Aug 2023.

Last reported valuation
$200.0M
Oct 2026
Priced at
—
Total raised
$78.7M
Last round
Early Stage VC
Aug 2023

Noveome Biotherapeutics key facts

as of Oct 2026
  • Developer of novel biotherapeutic products designed to treat inflamed or damaged tissues.
  • Noveome Biotherapeutics is valued at approximately $200.0M as of Oct 2026 (last reported valuation).
  • It has raised $78.7M across 4 recorded rounds; the latest was Early Stage VC ($36.2M) in Aug 2023.
  • Notable investors include UPMC Enterprises, Carnegie Mellon University, Commonwealth of Pennsylvania, MAK Capital, University of Pittsburgh Endowment — 10 tracked in total.
  • Noveome Biotherapeutics has filed 6 Form Ds with the SEC since 2016, most recently Aug 2024 ($36.2M sold to 66 investors).
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$200.0M

Noveome Biotherapeutics's last reported valuation, Apr 2019. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Noveome Biotherapeutics with a free account
  • ·Watch Noveome Biotherapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Noveome Biotherapeutics funding rounds

4 rounds
Aug 2023Early Stage VC$36.2MSEC filing▮
Sep 2020Seed Round$870KSEC filing▮
Jan 2018Early Stage VC$15.0MSEC filing▮
Dec 2015Seed Round$2.2MSEC filing▮
Full funding history →

Noveome Biotherapeutics valuation

Noveome Biotherapeutics's last reported valuation was $200 million in Apr 2019. No priced round, secondary trade or fund mark has surfaced since.

How much has Noveome Biotherapeutics raised?

Noveome Biotherapeutics has raised $78.7 million across 4 recorded rounds since 2015. The largest was an $870,000 seed round in Sep 2020; the most recent was a $36.2 million early-stage round in Aug 2023.

Noveome Biotherapeutics has filed 6 Form Ds with the SEC since 2016, most recently in Aug 2024 ($36.2 million sold to 66 investors).

Noveome Biotherapeutics investors

10 investors are on record for Noveome Biotherapeutics, including UPMC Enterprises, Carnegie Mellon University, Commonwealth of Pennsylvania and MAK Capital. The early-stage round in Aug 2023 drew 66 investors.

About Noveome Biotherapeutics

Developer of novel biotherapeutic products designed to treat inflamed or damaged tissues. The company's products contain numerous biologic components at physiologic concentrations which function in combination and synergistically to yield anti-inflammatory, neuroprotective, anti-apoptotic and vascular integrity preservative activities, enabling healthcare providers to provide treatment of complex diseases.

Sector
Healthcare
HQ
Pittsburgh, PA, United States
Founded
2000
Employees
26
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.